Ophthalmic medicine and treatment of diseases and injuries of the cornea

 

The invention relates to medicine, in particular to ophthalmology, and can be used as ophthalmic medicines for the treatment of diseases and injuries of the cornea. The tool includes a glycoprotein and a pharmaceutically acceptable carrier. Glycoprotein isolated from blood serum of mammals isoelectric focusing in a pH gradient with the selection of appropriate fractions, soluble in a saturated (100%) solution of ammonium sulfate has an isoelectric point in the pH range from 4.5 to 5.1 and apparent molecular mass from 10 to 37 kDa and possibly calcium chloride in the following ratio, wt.%: serum glycoprotein 110-16110-9; calcium chloride 00,01; media - the rest. The offered product is used by instillation on the cornea of the eye 2-7 fold within 10-15 days, both independently and in combination with other drugs. Ophthalmological tool used in the way that leads to the formation of a more delicate scar the cornea and reduces the risk of severe complications. 2 S. and 9 C.p. f-crystals, 1 Il., 6 table.top:2mm;">Claims

1. Ophthalmic drug, including glycoprotein and a pharmaceutically acceptable carrier, characterized in that it contains as a serum glycoprotein glycoprotein isolated from blood serum of mammals isoelectric focusing in a pH gradient with the selection of appropriate fractions, soluble in a saturated (100%) solution of ammonium sulfate having isoelectric point in the pH range from 4.5 to 5.1 and apparent molecular mass from 10 to 37 kDa and possibly calcium chloride in the following ratio, wt.%:

Serum glycoprotein 110-16- 110-9

Calcium chloride 0 - 0,01

Media Else

2. Means under item 1, characterized in that it contains components in the following ratio, wt.%:

Serum glycoprotein 110-16- 110-9

Calcium chloride 0,910-4- 0,01

Media Else

3. Means under item 1, characterized in that as the pharmaceutical carrier contains saline.

4. Means under item 1, characterized in that it contains the components is of LCI chloride 0,910-4- 1,110-4

Sodium chloride 0,86 - 0,92

Water To 100

5. The method of treatment of diseases and injuries of the cornea, characterized in that the use of pharmacological tool for PP.1-4 by installations on the cornea of the eye 2-7 fold within 10-15 days.

6. The method of treatment on p. 5, characterized in that used vehicle for PP.1-4 for the treatment of corneal erosion, States after penetrating and layer-by-layer keratoplasty eye, keratitis, burns and eye injuries.

7. The method of treatment on p. 5, characterized in that used vehicle for PP.1-4 in the postoperative period with the aim of improving the outcome of surgery on the eyes.

8. The method of treatment on p. 5, characterized in that used vehicle for PP.1-4 in the preoperative period with the aim of improving the outcome of surgery on the eyes.

9. The method of treatment on p. 5, characterized in that used vehicle for PP.1-4 to resolve adverse effects when wearing contact lenses.

10. The method of treatment on p. 5, characterized in that used vehicle for PP.1-4 to relieve discomfort and eye fatigue.

11. The method of treatment according to PP.5-10, characterized in that the means for PP.1-4 is used in combination with various drugs in video, reparative, anti-inflammatory (steroidal and nonsteroidal), dezintoksikatsionnye, antihistamines, vitamins, diuretics, specific catalysts (chemical burns), antioxidants, enzymes and proteolysis inhibitors, immunomodulators, mydriatic, vasodilator and vasoprotective, interleukins, as well as autohemotherapy.

 

Same patents:
The invention relates to medicine, in particular to ophthalmology, and can be used for the treatment of patients with diabetic retinopathy
The invention relates to medicine, in particular to ophthalmology, and can be used for the treatment of postinflammatory bullous keratopathy

The invention relates to medicine, namely to ophthalmology, and for the treatment of edematous maculopathy
The invention relates to medicine, namely to ophthalmology, and for the prevention of postoperative complications antiglaucomatous surgery
The invention relates to medicine, namely to ophthalmology, and for the treatment of endocrine ophthalmopathy

The invention relates to medicine, to the agent for the prevention or treatment of diseases associated with excessive proliferation of the epithelial pigment cells of the retina, such as proliferative vitreoretinopathy, and includes as the active ingredient N-(3,4-dimethoxycinnamoyl) Anthranilic acid of formula I or its pharmaceutically acceptable salt
The invention relates to medicine, namely to ophthalmology, and for the treatment of degenerative diseases of the retina
The invention relates to medicine, namely to ophthalmology, and for the correction of functional disorders of the visual analyzer

The invention relates to medicine, in particular to ophthalmology, and is intended to improve the treatment results of patients with blunt trauma of the eyeball, complicated intraocular hemorrhage

-converting enzyme)" target="_blank">

The invention relates to novel ortho-sulfonamidophenylhydrazine heteroaryl hydroxamic acids of the formula

< / BR>
where W and X are both carbon, T is nitrogen, U represents CR1where R1represents hydrogen, or alkyl containing 1-8 carbon atoms, R represents-N(CH2R5)-SO2Z, Q represents -(C=O)-NHOH, with

< / BR>
is a benzene ring, or is a heteroaryl ring of 5 to 6 atoms in the cycle, which may contain 0-2 heteroatoms selected from nitrogen, oxygen and sulfur, in addition to the heteroatom of nitrogen, denoted as W, where benzene or heteroaryl ring may optionally contain one or two substituent R1where permissible; Z is phenyl, which is optionally substituted by phenyl, alkyl with 1-8 carbon atoms, or a group OR2; R1represents halogen, alkyl with 1-8 carbon atoms, alkenyl with 2-6 carbon atoms, perfluoroalkyl from 1 to 4 carbon atoms, phenyl, optionally substituted by 1-2 groups OR2group-NO2group -(CH2)nZ, where Z is a phenyl which allows an alkyl with 1-8 carbon atoms, phenyl, optionally substituted with halogen, or heteroaryl radical containing 5 to 6 atoms in the cycle, including 1-2 heteroatoms selected from nitrogen, oxygen and sulfur; R5represents hydrogen, alkyl with 1-8 carbon atoms, phenyl, or heteroaryl containing 5 to 6 atoms in the cycle, including 1-2 heteroatoms selected from nitrogen, oxygen and sulfur; or their pharmaceutically acceptable salts
The invention relates to medicine, in particular, neurology, and can be used for the treatment of immune disorders in patients with demyelinating diseases (multiple sclerosis, multiple encephalomyelitis)

The invention relates to peptides having the amino acid sequence of at least 5 amino acids are identical to part ner receptor, corresponding to amino acids 308-373 this receptor, excluding the peptide TEKKRRETVEREKE

The invention relates to medicine and biology, more specifically a process for the production of collagen, and can be used in the treatment of various tissue pathologies, for cell cultivation

The invention relates to medicine, in particular to immunology, and for inhibition of lymphocyte proliferation

The invention relates to the field of medicine and biotechnology and concerns peptide antagonists Sonoline

The invention relates to venereology and, in particular, to the treatment of syphilis in the absence of positive to negative reactions Wasserman

The invention relates to medicine and for the treatment and prevention of cholelithiasis

The invention relates to medicine and relates to the use of proteins as antiretrovirals

The invention relates to medicine, and is intended for complex measured refractive treatment of astigmatism-related amblyopia in children
Up!